These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37828249)

  • 41. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. RTS,S/AS01
    Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
    Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of the potential for a malaria vaccine to reduce gaps in malaria intervention coverage.
    Unwin HJT; Mwandigha L; Winskill P; Ghani AC; Hogan AB
    Malar J; 2021 Nov; 20(1):438. PubMed ID: 34789253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
    RTS,S Clinical Trials Partnership
    PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
    ; Agnandji ST; Lell B; Soulanoudjingar SS; Fernandes JF; Abossolo BP; Conzelmann C; Methogo BG; Doucka Y; Flamen A; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Nhamuave A; Quelhas D; Bassat Q; Mandjate S; Macete E; Alonso P; Abdulla S; Salim N; Juma O; Shomari M; Shubis K; Machera F; Hamad AS; Minja R; Mtoro A; Sykes A; Ahmed S; Urassa AM; Ali AM; Mwangoka G; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Tahita MC; Kaboré W; Ouédraogo S; Sandrine Y; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Odero C; Oneko M; Otieno K; Awino N; Omoto J; Williamson J; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Nekoye O; Gondi S; Otieno A; Ogutu B; Wasuna R; Owira V; Jones D; Onyango AA; Njuguna P; Chilengi R; Akoo P; Kerubo C; Gitaka J; Maingi C; Lang T; Olotu A; Tsofa B; Bejon P; Peshu N; Marsh K; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Ayamba S; Kayan K; Owusu-Ofori R; Dosoo D; Asante I; Adjei G; Adjei G; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Kilavo H; Mahende C; Liheluka E; Lemnge M; Theander T; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Agyekum A; Owusu L; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Msika A; Jumbe A; Chome N; Nyakuipa D; Chintedza J; Ballou WR; Bruls M; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Vekemans J; Carter T; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
    N Engl J Med; 2011 Nov; 365(20):1863-75. PubMed ID: 22007715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modelling population-level impact to inform target product profiles for childhood malaria vaccines.
    Hogan AB; Winskill P; Verity R; Griffin JT; Ghani AC
    BMC Med; 2018 Jul; 16(1):109. PubMed ID: 30001708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Malaria Vaccines: Progress to Date.
    Stanisic DI; Good MF
    BioDrugs; 2023 Nov; 37(6):737-756. PubMed ID: 37728713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
    Vandoolaeghe P; Schuerman L
    Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of Novel Malaria Transmission-Blocking Vaccine Candidates.
    Takashima E; Tachibana M; Morita M; Nagaoka H; Kanoi BN; Tsuboi T
    Front Cell Infect Microbiol; 2021; 11():805482. PubMed ID: 34917521
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and Evaluation of a Cryopreserved Whole-Parasite Vaccine in a Rodent Model of Blood-Stage Malaria.
    Stanisic DI; Ho MF; Nevagi R; Cooper E; Walton M; Islam MT; Hussein WM; Skwarczynski M; Toth I; Good MF
    mBio; 2021 Oct; 12(5):e0265721. PubMed ID: 34663097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infectious diseases in children and adolescents in China: analysis of national surveillance data from 2008 to 2017.
    Dong Y; Wang L; Burgner DP; Miller JE; Song Y; Ren X; Li Z; Xing Y; Ma J; Sawyer SM; Patton GC
    BMJ; 2020 Apr; 369():m1043. PubMed ID: 32241761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lifting non-pharmaceutical interventions following the COVID-19 pandemic - the quiet before the storm?
    Oh KB; Doherty TM; Vetter V; Bonanni P
    Expert Rev Vaccines; 2022 Nov; 21(11):1541-1553. PubMed ID: 36039786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.
    Vandoolaeghe P; Schuerman L
    Expert Rev Vaccines; 2016 Dec; 15(12):1481-1493. PubMed ID: 27841689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
    Agnandji ST; Fernandes JF; Bache EB; Ramharter M
    Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study.
    Thompson HA; Hogan AB; Walker PGT; Winskill P; Zongo I; Sagara I; Tinto H; Ouedraogo JB; Dicko A; Chandramohan D; Greenwood B; Cairns M; Ghani AC
    Lancet Glob Health; 2022 Dec; 10(12):e1782-e1792. PubMed ID: 36400084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Malaria vaccines to moderate the impact of antibiotic resistance in endemic countries.
    Khan M; Khan S
    J Med Microbiol; 2023 Jul; 72(7):. PubMed ID: 37493512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Oct; 43(10):1515-1544. PubMed ID: 36456484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccines for preventing malaria (pre-erythrocytic).
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006198. PubMed ID: 17054280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RTS,S/AS01 vaccine (Mosquirix™): an overview.
    Laurens MB
    Hum Vaccin Immunother; 2020 Mar; 16(3):480-489. PubMed ID: 31545128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing the safety, impact and effectiveness of RTS,S/AS01
    Praet N; Asante KP; Bozonnat MC; Akité EJ; Ansah PO; Baril L; Boahen O; Mendoza YG; Haine V; Kariuki S; Lamy M; Maleta K; Mungwira R; Ndeketa L; Oduro A; Ogutu B; Olewe F; Oneko M; Orsini M; Roman F; Bahmanyar ER; Rosillon D; Schuerman L; Sing'oei V; Terlouw DJ; Wéry S; Otieno W; Pirçon JY
    Malar J; 2022 Apr; 21(1):132. PubMed ID: 35468801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.